Business Wire

WIKIFARMER

23.6.2022 10:02:13 CEST | Business Wire | Press release

Share
Wikifarmer Raises Large Seed Round From World Class Investors to Spread Sustainable Agricultural Knowledge Across the Globe and Digitize Agricultural B2B Commerce

Wikifarmer , a global platform with the mission of empowering farmers through educating them and offering them access to the open market to sell their products at fair prices and mentioned as the “Wikipedia of Farming” by the FAO of the UN, has successfully completed a Seed financing round with the support of a group of world class investors such as Mathias Kamprad, Inter IKEA BoD, Patrick and Cynthia Odier of the Lombard Odier Private Bank, Sophia Bendz, venture capitalist and former Spotify global director of marketing, Alexandre Vilgrain, C.E.O. of SOMDIAA group, the Constantakopoulos foundation and with the participation of Metavallon Venture Capital, a leading Greek VC firm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005694/en/

Agriculture is still one of the least digitized industries in the world and this has not allowed the industry’s value chain to be disrupted, but instead has created a paradox; farmers are the most valuable part of agriculture’s value chain but make the least profit out of it. In addition to that, most farmers are still using the techniques of their ancestors to grow their crops. The need for up-to-date sustainable agriculture knowledge has never been greater in the world than today. Agriculture & food trade market is expected to exceed 6 trillion EUR in value by the end of 2025.

Wikifarmer’s platform allows farmers to access free up to date knowledge on agricultural best practices and gives them the opportunity to sell their products directly to businesses, helping them minimize or surpass the large number of intermediaries that currently exist. Wikifarmer is aiming to become the universal source for farmers searching for information and the go-to destination for people seeking to purchase agricultural products globally.

Co-founders Ilias Sousis, Peter Sagos and Harry Parianos were inspired by the negative impact that outdated practices in agriculture have on the environment, global hunger and the financial sustainability of farmers. At the same time, helping farmers make a higher profit margin out of their commercial activities will have a wider impact on the economy and on the quality of products produced.

Sousis has been a part of the management team of Google Greece for years, leading the commercial launch of YouTube in Greece and Cyprus and has had prior entrepreneurial experience in traditional commerce, while Sagos is a passionate agronomist with deep knowledge in agricultural production and a business background as he was running a seeds trading family business. Parianos is the owner and CEO of McCann Athens and has spent more than 30 years as a senior leader in the advertising industry.

Wikifarmer’s library and marketplace has already been visited by 12 million visitors from more than 200 countries while 30,000 products have been uploaded by farmers. More than 5,000 buyers - including food processing units (FMCGs, Food services, etc), Wholesalers/ Importers, Retail Stores and Hotels/Restaurants - have purchased a product directly from a farm.

The investment will be used to expand the educational content to 20 languages and to enhance Wikifarmer’s marketplace presence in Greece, Italy, France and Spain, with the objective to create a Mediterranean hub of farmers that will attract buyers from all over the world, establishing the platform in a leading place globally.

Sagos said: “We want to democratize agriculture, give farmers around the world the chance to learn new things and thus the opportunity to grow their capabilities, their crops, their earnings. This is the only way forward to make this sector more sustainable and feed the growing world population.”

Ilias Sousis, mentioned regarding the raise: “I am thrilled that a group of very important and sustainability-conscious world-class investors are sharing our vision and efforts to solve some of the biggest pain points that have troubled the sector of agriculture for hundreds of years now.”

Link:

ClickThru

Social Media:

https://www.facebook.com/Wikifarmer.official/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye